# Weekly Docetaxel and Fixed-Dose Rate Gemcitabine Combination Chemotherapy

> **NCT00807261** · PHASE2 · UNKNOWN · sponsor: **Asan Medical Center** · enrollment: 30 (estimated)

## Conditions studied

- Sarcoma

## Interventions

- **DRUG:** Gemcitabine and Docetaxel

## Key facts

- **NCT ID:** NCT00807261
- **Lead sponsor:** Asan Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2008-09
- **Primary completion:** 2010-09
- **Final completion:** 2010-09
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2008-12-12

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00807261

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00807261, "Weekly Docetaxel and Fixed-Dose Rate Gemcitabine Combination Chemotherapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00807261. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*